Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Sophie V FletcherMark G JonesElizabeth A RenzoniHelen ParfreyRachel K HoylesKatherine SpinksMaria KokosiApollinaris KwokChris WarburtonVanessa TitmussMuhunthan ThillaiNicola SimlerToby M MaherChristopher J BreretonFelix ChuaAthol U WellsLuca RicheldiLisa G Spencer

Published in: ERJ open research (2018)

In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67.

Keyphrases

idiopathic pulmonary fibrosis
clinical practice
interstitial lung disease
randomized controlled trial
clinical trial
stem cells
rheumatoid arthritis
bone marrow
combination therapy
smoking cessation
replacement therapy
cell therapy